Biotheranostics to premiere new data on Breast Cancer Index™ and prediction of endocrine therapy benefit at SABCS 2020
08 déc. 2020 08h00 HE
|
Biotheranostics, Inc.
San Diego, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- New data on Biotheranostics’ Breast Cancer Index test will be highlighted at the 43rd annual San Antonio Breast Cancer Symposium (SABCS) being held...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
27 févr. 2020 06h30 HE
|
Jounce Therapeutics, Inc.
- On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 - - Ended 2019 with $170.4 million in...
Biotheranostics’ Pivotal Clinical Study of the Breast Cancer Index® featured on the cover of the Annals of Oncology
24 févr. 2020 08h00 HE
|
Biotheranostics, Inc.
San Diego, CA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- A pivotal clinical study validating Breast Cancer Index earns the distinction of being selected for the cover of the Annals of Oncology. The...
Jounce Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
09 janv. 2020 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present New Data on a Potential Predictive Biomarker from the Vopratelimab ICONIC Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting
19 déc. 2019 15h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016
20 avr. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new biomarker research associated with its clinical programs for anti-RSPO3...
OncoMed Presents Vantictumab Biomarker Data at the San Antonio Breast Cancer Symposium (SABCS)
11 déc. 2015 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Dec. 11, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) presented new data related to the development of a novel predictive biomarker for vantictumab...